Repurposed agents in the Alzheimer’s disease drug development pipeline | Alzheimer's Research & Therapy | Full Text

Repurposed agents in the Alzheimer’s disease drug development pipeline | Alzheimer's Research & Therapy | Full Text

Repurposed agents in the Alzheimer’s disease drug development pipeline

Treatments are needed to address the growing prevalence of Alzheimer’s disease (AD). Clinical trials have failed to produce any AD drugs for Food and Drug Administration (FDA) approval since 2003, and the phar...

Authors:Justin Bauzon, Garam Lee and Jeffrey Cummings

Citation:Alzheimer's Research & Therapy 2020 12:98

Content type:Research

 

Published on: 17 August 2020

• ViewFull Text
 
• ViewPDF